PYC Therapeutics jumps after U.S. FDA fast-track nod for eye disease drug

PYC Therapeutics

02/08/2023 05:11

** Shares of PYC Therapeutics Ltd  PYC.AX  rise as much as
15.5% to A$0.067, reaching their highest level since July 18
    ** Australia-based clinical biotech company says its VP-001
program received U.S. FDA fast-track designation
    ** VP-001 is a potential treatment for Retinitis Pigmentosa
type 11 (RP11), a blinding eye disease that begins in childhood
    ** Adds that drug candidate now eligible for accelerated
approval and priority review
    ** Stock has fallen 15.9% YTD, vs a 6.1% increase in the ASX
All Ordinaries index  .AORD 

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))